Trial Profile
RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS (RESTYLE- HCM STUDY)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2019
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Therapeutic Use
- Acronyms RESTYLE-HCM
- Sponsors Menarini
- 11 Jun 2019 Trial is prematurely ended in Italy.
- 11 Jun 2019 Status changed from recruting to completed.
- 22 Sep 2012 Planned End Date changed from 3 Jan 2013 to 19 Jan 2013 as reported by European Clinical Trials Database record.